**HPTN 084 Publications, Revised 31 January 2024**

**Manuscripts**

1. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribinwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC, on behalf of the HPTN 084 study group. (2022) [Cabotegravir for the Prevention of HIV-1 in Women: Results from HPTN 084, a Phase 3, Randomized Trial.](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00538-4/fulltext) Lancet, 399 (10337) 1779-1789.
2. Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S and Marzinke MA.(2022) [Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir on Tenofovir Disoproxil Fumarate/Emtritcitabine for HIV Prevention: HPTN 084.](https://academic.oup.com/jid/article/225/10/1741/6549543) Journal of Infectious Diseases, 225 (10): 1741-1749.
3. Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. [Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00251-X/fulltext). Lancet HIV. 2022 Dec;9(12):e857-e867. doi: 10.1016/S2352-3018(22)00251-X. Epub 2022 Nov 7. PMID: 36356603; PMCID: PMC9708606.
4. Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, Edupuganti S, Mgodi N, Rees H, Baeten JM, Gray G, Bekker LG, Hosseinipour M, Delany-Moretlwe S. [Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women](https://onlinelibrary.wiley.com/doi/10.1002/jia2.26118). J Int AIDS Soc. 2023 Jun;26(6):e26118. doi: 10.1002/jia2.26118. PMID: 37363917; PMCID: PMC10292682.
5. White RR, Dyer MC, Hosseinipour MC, Delany-Moretlwe S. [Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub-Saharan Africa community stakeholders](https://onlinelibrary.wiley.com/doi/10.1002/jia2.26120). J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26120. doi: 10.1002/jia2.26120. PMID: 37439067; PMCID: PMC10339002.
6. Preferences for Oral and Injectable PrEP among qualitative sub-study participants in HPTN 084. (Accepted for publication in PLOS ONE)

**Presentations**

1. Delany-Moretlwe S, Hosseinipour MC, Hosek S, Landovitz RJ, Grinsztejn B, Rinehart A, Cohen MS[. Long Acting Cabotegravir (CAB LA): Planning for Success across Global At-risk Populations](https://www.hptn.org/sites/default/files/inline-files/Delany_Moretlwe_0_0.png). Poster at AIDS 2020 (Virtual). 6-10 July 2020.
2. Delany-Moretlwe S, Hughes JP, Bock P, Gurrion S, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Mokgoro M, Mpendo J, Mukwekwerere P, Mgodi N, Nahirya Ntege P, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N. [Long Acting Injectable Cabotegravir is Safe and Effective in Preventing HIV Infection in Cisgender Women: Interim Results from HPTN 084.](https://vimeo.com/507992188/1a03d4fa0d) Oral Presentation at HIV R4P 2021. 27 & 28 January and 3 & 4 February 2021.
3. Marzinke M, Delany-Moretlwe S, Agyei Y, Piwowar-Manning E, Anderson P, Hendrix C, Rose S, Farrior J, Adeyeye A, Hanscom B, Rinehart A, Rooney JF, Cohen MS, Hosseinipour MC, Eshleman S, on behalf of the HPTN 084 study team. [Long-acting Injectable PrEP in Women: Laboratory Analysis of HIV Infections in HPTN 084](https://www.hptn.org/sites/default/files/inline-files/210708%20HPTN%20084%20Poster%20final.pdf). Poster Presentation at IAS 2021 (Virtual). 18-21 July 2021.
4. Moore M, Donnell DJ, Boily M-C, Mitchell KM, Delany-Moretlwe S, Hosseinipour MC, Hughes JP, Hanscom B, Dimitrov D. [Estimated Long-acting PrEP Effectiveness in the HPTN 084 Cohort using a Model-based HIV Incidence in the Absence of PrEP](https://www.hptn.org/sites/default/files/inline-files/IAS2021_MMoore_Final.pdf). Oral Presentation at IAS 2021 (Virtual). 18- 21 July 2021.
5. Delany-Moretlwe S, Hughes JP, Guo X, Hanscom B, Hendrix C, Farrior J, Berhanu RH, Rinehart A, Ford S, Rooney JF, Adeyeye A, Landovitz RJ, Cohen MS, Hosseinipour MC, Marzinke M. [Evaluation of CAB-LA Safety and PK In Pregnant Women in the Blinded Phase of HPTN 084](https://www.hptn.org/sites/default/files/inline-files/HPTN%20084%20evaluation%20of%20CAB%20LA%20safety%20and%20pk%20CROI%202022%20FINAL.pdf). Poster Presentation at CROI 2022. 12-16 February 2022.
6. Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, Edupuganti S, Mgodi N, Rees H, Baten J, Bekker L-G, Hosseinipour MC, Delany-Moretlwe S. [Counterfactual Estimation of CAB-LA Efficacy Against Placebo Using External Trial Data](https://www.hptn.org/sites/default/files/inline-files/CROI-2022-Women%27s%20Counterfactual.pdf). Oral Presentation at CROI 2022. 12-16 February 2022.
7. Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour M, Russell C, Meyer-Rath G. [The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis. A modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials](https://www.hptn.org/sites/default/files/inline-files/Meyer-Rath%20CAB%20CEA%20and%20threshold%20price%20in%20SA_Final.pdf). Oral Presentation at AIDS 2022. 29 July-02 August 2022.
8. Etima J, Tolley E, Bula A, Chitukuta M, Khoza N, Namey E, Kemigisha D, Makhale L, Tsidya M, Schrumpf L, Hosseinipour M, Delany-Moretlwe S, on behalf of the HPTN 084 study team. [Acceptability of injectable cabotegravir versus daily oral TDF/FTC for PrEP: Lesson from HPTN 084](https://www.hptn.org/sites/default/files/inline-files/INTEREST%202022_HPTN%20084%20Qual%20Substudy_Poster%20Final.pdf). Poster Presentation at INTEREST 2022. 10-13 May 2022.
9. Delany-Moretlwe S, Hughes JP, Bock P, Dadabhai S, Gadama D, Hunidzarira P, Innes S, Kalonji D, Makhema J, Mandima P, Mathew C, Mpendo J, Mukwekwerere P, Mgodi, Nahirya Ntege P, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Angira F, Singh N, Spooner E, Farrior J, Rose S, Berhanu R, Agyei Y, Eshleman SH, Marzinke M, Piwowar-Manning E, Beigel-Orme S, Hosek S, Adeyeye A, Rooney J, Rinehart A, Hanscom B, Cohen M, Hosseinipour M, on behalf of the HPTN 084 study team. [Long acting cabotegravir: updated efficacy and safety results from HPTN 084](https://www.hptn.org/sites/default/files/inline-files/220803%20IAS%202022%20HPTN%20084%20for%20HPTN%20website%20revised_0.pdf). Oral Presentation at AIDS 2022. 29 July-02 August 2022.
10. Khoza N, Etima J, Tolley E, Bula A, Chitukuta M, Namey E, Kemigisha D, Makhale L, Tsidya M, Schrumpf L, Hosseinipour M, Delany-Moretlwe S, on behalf of the HPTN 084 study team. [Acceptability of injectable cabotegravir versus daily oral TDF/FTC for PrEP: Lesson from HPTN 084](https://www.hptn.org/sites/default/files/inline-files/AIDS2022_HPTN%20084%20Qual%20Substudy_ReducedFileSize_Final.pdf). Poster Presentation at AIDS 2022. 29 July-02 August 2022.
11. Marzinke MA, Guo X, Hughes JP, Hanscom B, Piwowar-Manning E, Hendrix CW, Rose S, Rooney J, Rinehart AR, Ford S, Adeyeye A, Cohen M, Hosseinipour M, Delany-Moretlwe S for the HPTN 084 Study Team. [Cabotegravir Pharmacology in the Background of Delayed Injections in HPTN 084.](https://www.hptn.org/sites/default/files/inline-files/CROI%202023_Marzinke.pdf)  Oral Presentation at CROI 2023. 19-22 February 2023.
12. Delany-Moretlwe s, Hanscom B, Angira F, Dadabhai S, Gadama D, Mirembe B, Bhondai M, Innes S, Kalonji D, Makhema J, Mandima P, Marais A, Mpendo J, Mukwekwerere P, Mgodi N, Naidoo V, Nahirya- Ntege P, Nuwagaba-Biribonwoha H, Roos E, Singh N, Siziba B, Spooner E, Farrior J, Rose S, Piwowar-Manning E, Burton M, Soto-Torres L, Rooney J, Rinehart A, Cohen M, Hosseinipour M on behalf of the HPTN 084 study team. [Initial PrEP product choice: results from the HPTN 084 open-label extension.](https://www.hptn.org/sites/default/files/inline-files/220725%20IAS%202023%20product%20choice%20revised.pdf) Oral Presentation at IAS 2023. 23-26 July 2023.
13. Voldal E , Hanscom B, Eshleman S, Piwowar-Manning E, Agyei Y , Nyarota K , Angira F, Dadabhai S , Gadama D, Mirembe BG, Hunidzarira P, Innes S , Kalonji D , Makhema J, Mandima P , Marais A , Mpendo J, Mukwekwerere P, Mgodi N , Naidoo V, Nahirya Ntege P, Nuwagaba-Biribonwoha H, Roos E, Singh N, Siziba B , Spooner E , Farrior J, Rose S, Soto-Torres L, Rooney J, Rinehart AR, Landovitz R, Cohen MS, Delany-Moretlwe S for the HPTN 084 team. [Positive Predictive Value of HIV Serological Tests in HPTN 084 Trial.](https://www.hptn.org/sites/default/files/inline-files/IAS%20PPV%20HIV%20Serology%20testing%2025%20jul%202023.pdf) Oral Presentation at IAS 2023. 23-26 July 2023.
14. Etima, J, Tolley, E, Shoen M, Bula A, Chitukuta M, Khoza N, Namey E, Kemigisha D, Makhale L, Tsidya M, Wong C, Hosseiniour M, Delany-Moretlwe S, on behalf of the HPTN 084 study team. [Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study](https://www.hptn.org/sites/default/files/inline-files/IAS%202023%20Poster_HPTN%20084Q-Pregnancy_07%20JUL%2023_final.pdf). Poster Presentation at IAS 2023. 23-26 July 2023.
15. Bula A, Tsidya M, Makhale L, Khoza N, Etima J, Siziba B, Shoen M, Wong C, Tolley E, Hosseinipour M, Delany-Moretlwe S, on behalf of the HPTN 084 study team. “[Should I have my nose close to his?”: Perspective on the effects of COVID-19 on clinical trial participation and HIV risk among women in HPTN 084](https://www.hptn.org/sites/default/files/inline-files/BULA_Poster%20IAS_covid_Final_JULY%202023_Final.pdf). Poster Presentation at IAS 2023. 23-26 July 2023.